A large drop in the sale of drug coated stents knocked Boston Scientific’s (BSX) quarter way down. The company’s second-quarter profit, excluding charges, was $271 million, or 18 cents per share, compared with $412 million, or 31 cents per share, a year ago. Quarterly sales fell slightly to $2.1 billion.
Boston Scientific probably cannot solve the issue with its stent product. The medical community believes that the products can cause clotting and heart problems. That is unlikely to go away. Sales of its drug-eluting heart stents were $437 million in the quarter from $647 million last year.
That could get worse, and so could the stock price.
Douglas A. McIntyre
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
